National Framework Agreement for Adalimumab Injection 1 April 2023

Tender description

Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection commencing 1 April 2023<br/> <br/>Offer reference number: CM/PHR/22/5660<br/> <br/>CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months Lot 1: CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Lot 1 - CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Lot 3 - CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to the London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 4: CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Lot 4 - CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to the North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents